Parataxis Buys Biotech Firm to Build Korea’s First Public Bitcoin Treasury Company
Parataxis Holdings LLC is making bold moves in the digital asset world by investing KRW 25 billion ($18.2M) to take control of Bridge Biotherapeutics, a publicly traded biotech firm in South Korea.
The plan? Transform the company into “Parataxis Korea,” South Korea’s first publicly listed Bitcoin treasury firm. The move marks a major shift from biotech to Bitcoin and signals the rising institutional interest in BTC as a reserve asset.
Edward Chin, CEO of Parataxis Holdings, will join the board, while partner Andrew Kim will step in as CEO. Bridge’s biotech division will still be active, led by co-founder James Jungkue Lee.
With the shareholder vote scheduled for August 2025, this transformation could set a new standard for Bitcoin integration in public markets across Asia.
“We’re building Korea’s first institutional BTC treasury platform. This isn’t just a company shift—it’s a signal to the market,” said Chin.
Legal support comes from Shin & Kim LLC, with Deloitte as financial advisor. Parataxis continues to expand its Bitcoin-focused investment funds as part of this long-term strategy.
You might also like: Tether CEO Launches PearPass: Offline Password Manager After Record 16B Credential Leak